Clinical trials: Thromboelastography (TEG)
Anticoagulant Reversal, Reversal of Edoxaban Induced Anticoagulation
Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban
PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable safety and tolerability profile with no impact on pro-coagulant biomarkers.
- Trial name
- PER977-P1 (NCT01826266)
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Blood Coagulation Disorders, Thrombotic Disorders
Determination of Fibrin Activity in Plasma on STA-R® Prototype
The purpose of the study is to give the proof of concept of the Fibrin structure assay on STA-R® prototype. It aims to identify the parameters which discriminate the pathologic from the normal population.
- Conditions
- Blood Coagulation Disorders, Thrombotic Disorders, Hemorrhagic Disorders, Trauma
- Trial name
- FAST (NCT02856789)
- Testing
- Routine hemostasis tests, Fibrin structure (FS), Thromboelastography (TEG)
- Where
- France
- Volunteers
- 913 people, healthy volunteers welcome
- Sponsor
- Diagnostica Stago R&D
Fibrinogen Deficiency
Human Fibrinogen - Pharmacokinetics
This study evaluated the single-dose pharmacokinetics of human fibrinogen concentrate and clot strength (maximum clot firmness [MCF]) in subjects with congenital fibrinogen deficiency.
- Trial name
- NCT00496262
- Testing
- Human Fibrinogen Concentrate
- Where
- 15 sites in United States, Italy
- Volunteers
- 15 people
- Sponsor
- CSL Behring
Coagulation, Platelet Function
RapidTEG MA Validation
During normal physiological conditions hemostasis (the ability of blood to clot) is kept in homeostatic balance by feedback mechanisms.
- Trial name
- R-TEG MA (NCT01428102)
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Haemonetics Corporation
Coagulation
Thromboelastography (TEG) Reference Range Study
As part of a system wide reagent verification plan Haemoscope Corporation will be running a study to verify the reference intervals of many of the reagents.
- Trial name
- NCT01357928
- Where
- United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Haemonetics Corporation
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate the basal and spiked TEG® (Thromboelastography) or ROTEM® (Thromboelastometry) profiles of frequently bleeding…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- NCT01561924
- Testing
- eptacog alfa (activated)
- Where
- 7 sites in United States, Denmark and 2 more
- Volunteers
- 17 people
- Sponsor
- Novo Nordisk A/S
Heart Disease, Focus is on Testing Performance of CORA Hemostasis System.
Equivalency Study of the TEG and CORA Hemostasis Systems
This study is being performed to obtain data about the CORA system, a new device that is currently being tested and is not yet cleared for sale in the United State by the Food and Drug Administration (FDA).
- Trial name
- NCT01790386
- Where
- 4 sites in United States
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- Coramed Technologies LLC
Thrombocytopenia
Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)
The PRESS trial is a single-center, two-part, randomized cross-over pilot study in Copenhagen that will evaluate 1) the safety and performance of Mirasol-treated and untreated platelet products stored for 2-4 days and for 7-days…
- Trial name
- PRESS (NCT01368211)
- Testing
- 2-4-day-old Mirasol-treated Platelets Transfusion, 2-4-day-old Untreated Platelets Transfusion
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Terumo BCTbio